Careers  |  Sign In  |  Register

Latest in Oncology

Determining which patients are most likely to benefit from BRAF-targeted therapies was the topic of a recent review by Anna C. Pavlick, DO, MBA, of New York University Perlmutter Cancer Center, and colleagues, who noted that while research in this area in rapidly progressing, the answer to this important...
Determining which patients are most likely to benefit from BRAF-targeted therapies was the topic of a recent review in ASCO Educational Book by Anna C. Pavlick, DO, MBA, and colleagues at New York University Perlmutter Cancer Center, who noted that while research in this area is rapidly progressing, the...
A preliminary clinical study looking at previously untreated metastatic melanoma showed promising results when treating with the combination of an IL-2 signaling agonist and nivolumab. Primary trial objectives consisted of safety and tolerability, objective response rate, and a per-protocol efficacy...